Changes within the thyroid axis after long-term TSH-suppressive levothyroxine therapy. - Wikidata - wikimedia - TriplyDB

Changes within the thyroid axis after long-term TSH-suppressive levothyroxine therapy.

Changes within the thyroid axis after long-term TSH-suppressive levothyroxine therapy.

http://www.wikidata.org/entity/Q34226270

about

Homeostatic Control of the Thyroid-Pituitary Axis: Perspectives for Diagnosis and Treatment Radioiodine Treatment and Thyroid Hormone Suppression Therapy for Differentiated Thyroid Carcinoma: Adverse Effects Support the Trend toward Less Aggressive Treatment for Low-Risk Patients The relationship of 19 functional polymorphisms in iodothyronine deiodinase and psychological well-being in hypothyroid patients.

P2860

Q26774730-06130175-9361-48FC-9A55-070D5B9BA1C5 Q26797677-D992D809-2D6E-47FA-9B61-9DDFD30F5D54 Q36361581-17A8CBDB-8623-473F-BFFE-09D650F9E630

P2860

Changes within the thyroid axis after long-term TSH-suppressive levothyroxine therapy.

http://www.wikidata.org/entity/Q34226270

description

2012 nî lūn-bûn

@nan

2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Changes within the thyroid axis after long-term TSH-suppressive levothyroxine therapy.

@ast

Changes within the thyroid axis after long-term TSH-suppressive levothyroxine therapy.

@en

Changes within the thyroid axis after long-term TSH-suppressive levothyroxine therapy.

@nl

type

label

Changes within the thyroid axis after long-term TSH-suppressive levothyroxine therapy.

@ast

Changes within the thyroid axis after long-term TSH-suppressive levothyroxine therapy.

@en

Changes within the thyroid axis after long-term TSH-suppressive levothyroxine therapy.

@nl

prefLabel

Changes within the thyroid axis after long-term TSH-suppressive levothyroxine therapy.

@ast

Changes within the thyroid axis after long-term TSH-suppressive levothyroxine therapy.

@en

Changes within the thyroid axis after long-term TSH-suppressive levothyroxine therapy.

@nl

P1433

Q34226270-95E75F30-0C21-4D1B-BEBB-BF51FCC411FC

P1476

Q34226270-079164BC-33A4-42FC-8368-942434980FB5

P2093

Q34226270-5A3E77F2-4B9E-4A1D-96C0-F9161CA392E5

Q34226270-630F1E10-CAC6-402B-B6DF-0C2D034B5B27

Q34226270-68CDEBE7-22C2-4966-A035-7896FE6FBF72

Q34226270-78EBE710-6B9D-4A48-B6E5-8C9CD46EEF5D

Q34226270-E2327D51-99F2-4D33-AD4D-8F05477F1607

Q34226270-FAEF514D-C794-42C8-A885-2D722268981F

P2860

Q34226270-00238BD9-E265-4663-9381-17B67F8E70CF

Q34226270-24B6AD56-F6C9-498E-8BA6-A1D093B1D46C

Q34226270-2DC9DCB8-E13D-4CAA-851A-CAF46A1C26AD

Q34226270-53ED8F79-428E-41D2-A31C-D3BF484A2FC3

Q34226270-55064CA4-1551-4B18-9A47-B4CCA05F7CFD

Q34226270-59E3AFAE-F45C-42E1-B3C1-9EAE7529A4F1

Q34226270-66C01DCD-3102-4E7A-81DD-9BFDC1F0B3E5

Q34226270-9DEBE4D8-009C-485E-BE5E-816DDDA71D49

Q34226270-C13BE32A-0111-43CD-B106-34753DAC0ED6

Q34226270-EFB76BD4-5573-4A7D-A889-5769D56CB95B

P304

Q34226270-7DB3DE6C-C7B1-4AB9-91EC-D72C12B3F75D

P31

Q34226270-3AA7492B-2D68-42B7-ABA7-AC8254A64C5B

P356

Q34226270-49454FAA-F9A0-45AD-8D3F-E9F690D5EAA8

P433

Q34226270-05E34DF3-E564-4A75-84BE-E1041DF12F49

P478

Q34226270-51542E65-B4CA-4EEB-9BF6-A691EBD2BC4F

P577

Q34226270-90B0E667-BA27-49B9-9539-9EC9634B9797

P698

Q34226270-88614552-924D-48D2-9754-DD04A4D62E4E

P356

J.1365-2265.2011.04262.X

P1433

Clinical Endocrinology

P1476

Changes within the thyroid axis after long-term TSH-suppressive levothyroxine therapy.

@en

P2093

Christoph Reiners

http://www.w3.org/2001/XMLSchema#string

Frederik A Verburg

http://www.w3.org/2001/XMLSchema#string

Inge Grelle

http://www.w3.org/2001/XMLSchema#string

Johannes W A Smit

http://www.w3.org/2001/XMLSchema#string

Robin P Peeters

http://www.w3.org/2001/XMLSchema#string

Theo J Visser

http://www.w3.org/2001/XMLSchema#string

P2860

Thyrotropin receptor autoantibodies are associated with continued thyrotropin suppression in treated euthyroid Graves' disease patients

Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer

Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer.

Serum 3,3',5'-triiodothyronine (rT3) and 3,5,3'-triiodothyronine/rT3 are prognostic markers in critically ill patients and are associated with postmortem tissue deiodinase activities.

European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium.

The effects of thyrotropin-suppressive therapy on bone metabolism in patients with well-differentiated thyroid carcinoma.

Primary tumour diameter as a risk factor for advanced disease features of differentiated thyroid carcinoma.

Histology does not influence prognosis in differentiated thyroid carcinoma when accounting for age, tumour diameter, invasive growth and metastases.

Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients.

Thyroid over-expression of type 1 and type 2 deiodinase may account for the syndrome of low thyroxine and increasing triiodothyronine during propylthiouracil treatment.

P304

577-581

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2265.2011.04262.X

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

76

http://www.w3.org/2001/XMLSchema#string

P577

2012-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22017394

http://www.w3.org/2001/XMLSchema#string